Twist Bioscience (NASDAQ:TWST) Price Target Lowered to $33.00 at JPMorgan Chase & Co.

Twist Bioscience (NASDAQ:TWST) had its price objective dropped by stock analysts at JPMorgan Chase & Co. from $40.00 to $33.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 8.15% from the company’s previous close.

TWST has been the topic of a number of other research reports. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Barclays cut their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price objective on shares of Twist Bioscience in a research note on Friday, March 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $52.10.

Twist Bioscience Stock Down 8.4 %

Twist Bioscience stock opened at $35.93 on Tuesday. Twist Bioscience has a 1-year low of $33.16 and a 1-year high of $60.90. The business has a fifty day moving average price of $39.13 and a 200-day moving average price of $43.98. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -10.63 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Equities research analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,726 shares of Twist Bioscience stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the sale, the chief executive officer now owns 660,966 shares of the company’s stock, valued at $27,549,062.88. The trade was a 0.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Patrick John Finn sold 2,058 shares of the stock in a transaction dated Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the completion of the sale, the chief operating officer now owns 265,460 shares of the company’s stock, valued at $10,615,745.40. This trade represents a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,137 shares of company stock valued at $530,112 over the last quarter. 3.01% of the stock is currently owned by insiders.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc grew its position in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after purchasing an additional 580 shares in the last quarter. GAMMA Investing LLC grew its holdings in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares in the last quarter. Van ECK Associates Corp grew its holdings in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience during the third quarter worth about $34,000. Finally, Banque Transatlantique SA purchased a new position in Twist Bioscience during the fourth quarter worth about $43,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.